英文互译镜像站

Rachael L. Morton

Last updated

Rachael L. Morton is an Australian academic, Professor and Principal Research Fellow of Health Economics in the Faculty of Medicine and Health, University of Sydney. [1]

Contents

Morton is an international leader in the economic evaluation of chronic kidney disease and melanoma skin cancer.[ citation needed ]

Education and Career

Morton graduated with a PhD from the University of Sydney in 2011. [2]

Morton is currently Director of Health Economics & Health Technology Assessment and deputy director of the NHMRC Clinical Trials Centre. [1]

Board Director, Australian Clinical Trials Alliance [3] (ACTA) 2018–2024; Past President, Heath Services Research Association Australia and New Zealand [4] (HSRAANZ); Program Chair - International Health Economics Association [5] (IHEA); Health Economists Study Group UK [6] (HESG). [1]

Health Economics Research

Morton is an international leader in the economic evaluation of chronic kidney disease and melanoma prevention, diagnosis, and treatment.[ citation needed ]

Morton's research has had a major influence on funding policy (US Medicare & Medicaid) for dialysis payments and chronic kidney disease; [7] [ failed verification ] Australian Medicare providing economic evidence for new MBS items. [8] Her research has changed international clinical practice guidelines in melanoma (UK, US, Germany, Brazil, Australia [9] ) kidney disease (Kidney Disease Improving Global Outcomes [KDIGO] guidelines, [10] CARI [Australia]), for transplantation and end-of-life care; and infectious diseases through the European Centre for Disease Control [EU].

Awards and recognition

In 2013 Morton won an NHMRC Sidney Sax Fellowship to Oxford University.[ citation needed ]

In 2019 CI Morton won the Distinguished Investigator award for Health Services Research. [11]

In 2024, Morton won the ACTA Trial of the Year, Health Economics Alongside Trials (HEAT) Excellence award for her high impact cost-effectiveness analysis of a melanoma prevention strategy using personalised genomics. [12] [13]

Additionally in 2024, Morton was a winner in the Eureka Science Prize – Aspire Scholarship Excellence in Interdisciplinary Scientific Research, for the ACRF Australian Centre for Excellence in Melanoma Imaging and Diagnosis. [14]

Top Publications

Source: [15]

1.   The views of patients and carers in treatment decision making for chronic kidney disease: a systematic review and thematic synthesis of qualitative studies. BMJ. [16]

2.   Chronic Kidney Disease. The Lancet. [17]

3.   Cost-Effectiveness of Skin Surveillance Through a Specialized Clinic for Patients at High Risk of Melanoma. Journal of Clinical Oncology. [18]

4.   The effectiveness and cost-effectiveness of screening for latent tuberculosis among migrants in the EU/EEA: a systematic review. Euro Surveillance. [19]

5.   Impact of CKD on Household Income. Kidney International Reports. [20]

6.   Incorporating carbon into health care: adding carbon emissions to health technology assessments. The Lancet Planetary Health. [21]

7.   The Symptom Monitoring with Feedback Trial (SWIFT): Protocol for a registry-based cluster randomised controlled trial in haemodialysis. Trials. [22]

8.   Patient- reported outcome measures (PROMs) to guide clinical care: recommendations and challenges. MJA. [23]

9.    Kidney health in the context of economic development. Nature Reviews, Nephrology. [24]

10.  Expedited transfer from scene for refractory out-of-hospital cardiac arrest: an Australian prospective, multicentre, parallel, open-label randomised clinical trial. Accepted The Lancet Respiratory Medicine. (May, 2025)

References

  1. 1 2 3 Morton, Rachael (2025-07-21). "People". Th University of Sydney.
  2. ↑ Morton, Rachael (2025-07-21). "Profile/rachaelmorton". Linked In.
  3. ↑ "ACTA – Australian Clinical Trials Alliance – Better health through best evidence". clinicaltrialsalliance.org.au/.
  4. ↑ "HSRAANZ - Using research to improve health services & systems". HSRAANZ.
  5. ↑ "Home". IHEA.
  6. ↑ "Health Economists' Study Group – The UK Health Economics Association". March 1, 2019.
  7. ↑ "Medicare Program; End-Stage Renal Disease Prospective Payment System, Payment for Renal Dialysis Services Furnished to Individuals With Acute Kidney Injury, Conditions for Coverage for End-Stage Renal Disease Facilities, End-Stage Renal Disease Quality Incentive Program, and End-Stage Renal Disease Treatment Choices Model". Federal Register. 2024-11-12. Retrieved 2025-07-22.
  8. ↑ https://www.msac.gov.au/sites/default/files/documents/1485.1%2520Final%2520PSD_Apr2020.pdf
  9. ↑ https://www.cancer.org.au/assets/pdf/archived-diagnosis-and-management-of-melanoma-guidelines-11-june-2018
  10. ↑ Davison, Sara N.; Levin, Adeera; Moss, Alvin H.; Jha, Vivekanand; Brown, Edwina A.; Brennan, Frank; Murtagh, Fliss E. M.; Naicker, Saraladevi; Germain, Michael J.; O'Donoghue, Donal J.; Morton, Rachael L.; Obrador, Gregorio T. (2015-09-01). "Executive summary of the KDIGO Controversies Conference on Supportive Care in Chronic Kidney Disease: developing a roadmap to improving quality care" . Kidney International. 88 (3): 447–459. doi: 10.1038/ki.2015.110 . ISSN   0085-2538. PMID   25923985.
  11. ↑ Green, Sarah (2019-12-12). "A/Professor Rachael Morton - Distinguished Investigator (Mid-Career)". HSRAANZ. Retrieved 2025-07-22.
  12. ↑ "NHMRC Clinical Trial Centre | Improving Health Outcomes". ctc.usyd.edu.au. Retrieved 2025-07-21.
  13. ↑ "Australian Clinical Trials shine at annual ACTA Awards – ACTA – Australian Clinical Trials Alliance". clinicaltrialsalliance.org.au/. 2024-05-20. Retrieved 2025-07-21.
  14. ↑ News, Opening Hours Open Daily 10am-5pmClosed Christmas DayFree General Entry Address 1 William StreetSydney NSW 2010 Australia Phone +61 2 9320 6000 www australian museum Copyright © 2025 The Australian Museum ABN 85 407 224 698 View Museum. "2024 Australian Museum Eureka Prizes finalists". The Australian Museum. Retrieved 2025-07-21.{{cite web}}: |last= has generic name (help)CS1 maint: numeric names: authors list (link)
  15. ↑ "Rachael Morton". scholar.google.com.au. Retrieved 2025-07-21.
  16. ↑ Morton, R. L.; Tong, A.; Howard, K.; Snelling, P.; Webster, A. C. (2010-01-19). "The views of patients and carers in treatment decision making for chronic kidney disease: systematic review and thematic synthesis of qualitative studies". BMJ. 340: c112. doi:10.1136/bmj.c112. ISSN   0959-8138. PMC   2808468 . PMID   20085970.
  17. ↑ Webster, Angela C.; Nagler, Evi V.; Morton, Rachael L.; Masson, Philip (2017-03-25). "Chronic Kidney Disease" . The Lancet. 389 (10075): 1238–1252. doi:10.1016/S0140-6736(16)32064-5. ISSN   0140-6736. PMID   27887750.
  18. ↑ Watts, Caroline G.; Cust, Anne E.; Menzies, Scott W.; Mann, Graham J.; Morton, Rachael L. (January 2017). "Cost-Effectiveness of Skin Surveillance Through a Specialized Clinic for Patients at High Risk of Melanoma". Journal of Clinical Oncology. 35 (1): 63–71. doi:10.1200/JCO.2016.68.4308. hdl: 2123/30021 . ISSN   0732-183X. PMID   28034073.
  19. ↑ Greenaway, Christina; Pareek, Manish; Abou Chakra, Claire-Nour; Walji, Moneeza; Makarenko, Iuliia; Alabdulkarim, Balqis; Hogan, Catherine; McConnell, Ted; Scarfo, Brittany; Christensen, Robin; Tran, Anh; Rowbotham, Nick; van der Werf, Marieke J.; Noori, Teymur; Pottie, Kevin (April 2018). "The effectiveness and cost-effectiveness of screening for latent tuberculosis among migrants in the EU/EEA: a systematic review". Euro Surveillance. 23 (14): 17–00543. doi:10.2807/1560-7917.ES.2018.23.14.17-00543. ISSN   1560-7917. PMC   5894253 . PMID   29637889.
  20. ↑ Morton, Rachael L.; Schlackow, Iryna; Gray, Alastair; Emberson, Jonathan; Herrington, William; Staplin, Natalie; Reith, Christina; Howard, Kirsten; Landray, Martin J.; Cass, Alan; Baigent, Colin; Mihaylova, Borislava; Collins, R.; Baigent, C.; Landray, M. J. (2018-05-01). "Impact of CKD on Household Income". Kidney International Reports. 3 (3): 610–618. doi:10.1016/j.ekir.2017.12.008. ISSN   2468-0249. PMC   5976816 . PMID   29854968.
  21. ↑ McAlister, Scott; Morton, Rachael L.; Barratt, Alexandra (2022-12-01). "Incorporating carbon into health care: adding carbon emissions to health technology assessments". The Lancet Planetary Health. 6 (12): e993 –e999. doi:10.1016/S2542-5196(22)00258-3. hdl: 2123/30261 . ISSN   2542-5196. PMID   36495894.
  22. ↑ Greenham, Lavern; Bennett, Paul N.; Dansie, Kathryn; Viecelli, Andrea K.; Jesudason, Shilpanjali; Mister, Rebecca; Smyth, Brendan; Westall, Portia; Herzog, Samuel; Brown, Chris; Handke, William; Palmer, Suetonia C.; Caskey, Fergus J.; Couchoud, Cecile; Simes, John (2022-05-19). "The Symptom Monitoring with Feedback Trial (SWIFT): protocol for a registry-based cluster randomised controlled trial in haemodialysis". Trials. 23 (1): 419. doi: 10.1186/s13063-022-06355-0 . ISSN   1745-6215. PMC   9118566 . PMID   35590395.
  23. ↑ https://www.mja.com.au/system/files/issues/216_01/mja251355.pdf
  24. ↑ Morton, Rachael L.; Shah, Karan K. (January 2021). "Kidney health in the context of economic development". Nature Reviews Nephrology. 17 (1): 5–6. doi:10.1038/s41581-020-00376-1. ISSN   1759-507X. PMC   7684194 . PMID   33235390.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.
蚂蚁镜像站群 网站镜像克隆 网站复制工具 网站克隆 镜像软件